How can cutting-edge techniques and robust experimental systems solve drug development challenges? Scantox is delighted to share our solutions at the Boston central nervous system (CNS) Therapeutics Xchange Meeting 2024 on June 24.
The event will host around 60 attendees, bringing together leading executives from the pharmaceutical and biotechnology sectors. It provides the ideal environment for in-depth, face-to-face discussions and exploring new partnership opportunities. At the event, Scantox expert Stefan Ebner-Benke will present “A Guide through Preclinical Drug Testing Systems for Neuroinflammation.” He will outline our integrated approaches to studying neuroinflammatory processes and discuss the most effective model systems for each drug development stage. Additionally, Stefan will present our approach to generating detailed, in-house data with a strong focus on consistency and data integrity. Unlike many competitors, we transparently communicate how our experimental systems are validated. This commitment guarantees the models’ effectiveness and provides clients tangible and defendable results for their neuroinflammation research projects. Our thorough understanding of these systems and direct scientist-to-scientist communication ensures that our customers receive accurate and actionable information about what to expect from the start.
If your organization seeks a comprehensive suite of experimental systems backed by extensive experience and technical skills in neuroinflammation, we invite you to engage directly with Ewald and Stefan at the event.
This meeting is an excellent opportunity to discuss in detail how we can tailor our solutions to the needs of your R&D projects.
